Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 564 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma EMA Recommends Extending Indications for Lisocabtagene Maraleucel Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over... MOST POPULAR Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... March 11, 2025 A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... August 29, 2023 Innovative cancer spinouts: 3 new projects get green light August 13, 2021 This Harmful Chemical Is Still Being Used In Popular Household Products June 15, 2021 Load more HOT NEWS Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and... New on NCI’s Websites for September 2022 Can mRNA Vaccines Help Treat Cancer?
